NCT00425646View on ClinicalTrials.gov

Imatinib Mesylate and Bevacizumab After First-Line Chemotherapy and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

October 31, 2007

Study Completion Date

July 31, 2009

Conditions
Lung Cancer
Interventions
BIOLOGICAL

bevacizumab

DRUG

imatinib mesylate

Trial Locations (1)

98109-1023

Seattle Cancer Care Alliance, Seattle

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Washington

OTHER

NCT00425646 - Imatinib Mesylate and Bevacizumab After First-Line Chemotherapy and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter